one of India's leading pharmaceutical companies with operations across the globe has launched TOFATAS – a DCGI-approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate ...

Minghui Pharmaceutical has reported positive topline outcomes from the randomised Phase III trial of its pan-Jak inhibitor, ...

Among participants in the landmark ORAL Surveillance study assigned to the JAK inhibitor tofacitinib (Xeljanz) and also using statins, major adverse cardiovascular events (MACE) were no more ...